Penpulimab vs Tislelizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: PD-1 · full Non-Small Cell Lung Cancer pipeline
Penpulimab
Marketed by Akeso and partners
NCT03866993 · Phase 3 · completed
This was a randomized, double-blind, placebo-controlled Phase 3 trial in 350 patients with advanced squamous non-small-cell lung cancer, all of whom also received paclitaxel and carboplatin. An independent radiology committee assessed progression-free survival in two primary populations: all randomized patients and the PD-L1-positive subgroup. Penpulimab improved progression-free survival in both populations (median 7.6 vs 4.2 months overall and 8.1 vs 4.2 months in PD-L1-positive patients, both p<0.0001), so the trial met its primary endpoint. The figures come from the peer-reviewed Lancet Respiratory Medicine paper.
Reported efficacy
Progression-free survival (PFS) in intent-to-treat (ITT) population, assessed by Independent Radiologist Review Committee(IRRC) in accordance with RECIST v1.1 (Up to approximately 2 years); PFS in PD-L1-selected population, assessed by IRRC in accordance with RECIST v1.1 (Up to approximately 2 years): Primary 1, IRRC-assessed PFS in the ITT population (final analysis): median 7.6 months (95% CI 6.8 to 9.6) penpulimab + chemotherapy vs 4.2 months (95% CI 4.2 to 4.3) placebo + chemotherapy; HR 0.43 (95% CI 0.33 to 0.56); p<0.0001, met. Primary 2, IRRC-assessed PFS in the PD-L1-positive subgroup: median 8.1 vs 4.2 months; HR 0.37 (95% CI 0.27 to 0.52); p<0.0001, met. (met)
Result source: NCT03866993
Tislelizumab
Marketed by BeOne Medicines and partners
NCT03358875 · Phase 3 · completed
The 805-participant trial was randomized and actively controlled with docetaxel, and its co-primary clinical endpoint of overall survival was met in both the full population and the PD-L1-positive subgroup. However, treatment assignment was not blinded, so despite the large sample and statistically significant survival results, the evidence is rated moderate rather than strong.
Next expected readout: November 2026 · NCT06704620 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Penpulimab | Tislelizumab |
|---|---|---|
| PFS, median | 8.6 vs 4.2a+4.4 vs placeboNCT03866993 | 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT035947475 other results
|
| OS, median | —Not posted · NCT03866993 | 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT035947471 other result
|
| ORR | —Not posted · NCT03866993 | 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT035947473 other results
|
| Duration of response, median | —Not posted · NCT03866993 | 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT035947473 other results
|
PFS, median
- Penpulimab
- 8.6 vs 4.2a+4.4 vs placeboNCT03866993
- Tislelizumab
- 7.6 vs 5.5vs Paclitaxel + CarboplatinNCT03594747
5 other results
- 7.6 vs 5.5 NCT03594747
- 7.7 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.6 vs 5.5 NCT03594747
- 9.8 vs 5.5 NCT03594747
OS, median
- Penpulimab
- —Not posted · NCT03866993
- Tislelizumab
- 26.1 vs 19.4vs Paclitaxel + CarboplatinNCT03594747
1 other result
- 23.3 vs 19.4 NCT03594747
ORR
- Penpulimab
- —Not posted · NCT03866993
- Tislelizumab
- 74.2% vs 47.9%vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 73.9% vs 47.9% NCT03594747
- 70% vs 49.6% NCT03594747
- 78.2% vs 49.6% NCT03594747
Duration of response, median
- Penpulimab
- —Not posted · NCT03866993
- Tislelizumab
- 8.4 vs 4.3vs Paclitaxel + CarboplatinNCT03594747
3 other results
- 8.6 vs 4.3 NCT03594747
- 10.6 vs 4.8 NCT03594747
- 8.8 vs 4.8 NCT03594747
- a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Penpulimab: 0 of 4 rows · Tislelizumab: 2 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Penpulimab | Tislelizumab |
|---|---|---|
| Dropout rate | — | n/a: no completion milestoneTislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultn/a: no completion milestoneTislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Discontinued due to AEs | — | —Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result—Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Serious AEs | — | 46.6%Tislelizumab + Nab-paclitaxel + Caa NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more result46.7%Tislelizumab + Paclitaxel + Carbop NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
| Most frequent reported AEs | — | a anaemia 94.1% alopecia 69.5% neutrophil count decreased 61.9% NCT03594747 · Phase 3 · registry result, not featured evidence · combination show 1 more resultanaemia 89.2% alopecia 65% neutrophil count decreased 65% NCT03594747 · Phase 3 · registry result, not featured evidence · combination |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Tislelizumab
show 1 more result
show 3 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
Nasopharyngeal Carcinoma
Shared mechanism: PD-1 · full Nasopharyngeal Carcinoma pipeline
Penpulimab
Marketed by Akeso and partners
NCT04974398 · Phase 3 · active, not recruiting
Patients were randomly assigned to penpulimab or a matching placebo with patients, doctors and assessors all blinded, and the trial met its primary endpoint, progression-free survival judged by blinded central review. A power calculation was reported, and 291 patients were randomized against a planned 278.
No aligned efficacy figure on record for this race.
Tislelizumab
Marketed by BeOne Medicines and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT06177301 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Nasopharyngeal Carcinoma
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Penpulimab: no structured comparison results are available for Nasopharyngeal Carcinoma.
Tislelizumab: registry results are on file for Nasopharyngeal Carcinoma, but their comparison mappings are not yet available.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Penpulimab's landscape · Tislelizumab's landscape